206 related articles for article (PubMed ID: 36077631)
1. Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art.
Feola T; Carbonara F; Verrico M; Di Crescenzo RM; Gianno F; Colonnese C; Arcella A; de Alcubierre D; Tomao S; Esposito V; Giangaspero F; Minniti G; Jaffrain-Rea ML
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077631
[TBL] [Abstract][Full Text] [Related]
2. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Ilie MD; Villa C; Cuny T; Cortet C; Assie G; Baussart B; Cancel M; Chanson P; Decoudier B; Deluche E; Di Stefano AL; Drui D; Gaillard S; Goichot B; Huillard O; Joncour A; Larrieu-Ciron D; Libe R; Nars G; Vasiljevic A; Raverot G
Eur J Endocrinol; 2022 Nov; 187(5):685-696. PubMed ID: 36111659
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review.
Ilie MD; Vasiljevic A; Jouanneau E; Raverot G
Endocr Relat Cancer; 2022 May; 29(7):415-426. PubMed ID: 35521777
[TBL] [Abstract][Full Text] [Related]
5. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
6. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.
Raverot G; Ilie MD
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101712. PubMed ID: 36274025
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary.
Marques P
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345047
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature.
Duhamel C; Ilie MD; Salle H; Nassouri AS; Gaillard S; Deluche E; Assaker R; Mortier L; Cortet C; Raverot G
J Pers Med; 2020 Aug; 10(3):. PubMed ID: 32823651
[TBL] [Abstract][Full Text] [Related]
10. Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
[TBL] [Abstract][Full Text] [Related]
11. Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors.
Guo X; Yang Y; Qian Z; Chang M; Zhao Y; Ma W; Wang Y; Xing B
Cancer Lett; 2024 Jun; 592():216908. PubMed ID: 38677640
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract][Full Text] [Related]
13. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
14. Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.
Øystese KAB; Casar-Borota O; Berg-Johnsen J; Berg JP; Bollerslev J
Endocrine; 2022 Jun; 77(1):151-159. PubMed ID: 35674926
[TBL] [Abstract][Full Text] [Related]
15. Emerging and Novel Treatments for Pituitary Tumors.
Ilie MD; Lasolle H; Raverot G
J Clin Med; 2019 Jul; 8(8):. PubMed ID: 31349718
[TBL] [Abstract][Full Text] [Related]
16. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
17. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
18. Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.
Iglesias P
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202123
[TBL] [Abstract][Full Text] [Related]
19. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
20. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
